🧬 BioMed Pulse · 2026-07-02 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Wednesday, July 2, 2026 | 02:00 UTC

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now passed 896 confirmed cases and 232 deaths as of June 17, remaining an active WHO Public Health Emergency of International Concern — the dominant global health story of mid-2026. Separately, CDC issued a holiday-weekend alert on an unusually early and record-pace West Nile virus season in the United States, signaling a tense summer ahead on multiple infectious-disease fronts.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA — PHEIC ONGOING

• As of June 17, 2026, 896 confirmed cases and 232 deaths have been reported from DRC, with cross-border transmission continuing in Uganda. ^[1]
• WHO declared the Bundibugyo virus disease (BVD) epidemic a Public Health Emergency of International Concern on May 17, 2026; the IHR Emergency Committee confirmed the PHEIC designation does not yet meet criteria for pandemic emergency. ^{[2] [3]}
• Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, 2026, seeking to raise US$518 million to support African countries at risk of spread. ^[4]
• WHO issued its first comprehensive clinical management guidelines for all filovirus diseases — covering all Ebola types and Marburg — on June 17, 2026, directly in response to the BVD outbreak. ^[5]
• WHO convened expert advisory groups on May 28 to assess candidate treatments and vaccines specifically for Bundibugyo virus; no approved therapeutic currently exists for this strain. ^[6]
• CDC mobilized an international Ebola response as of May 17, 2026, and has expanded enhanced airport entry screening to Washington-Dulles and Atlanta Hartsfield-Jackson airports. ^{[7] [8] [9]}

WEST NILE VIRUS — UNITED STATES

• CDC issued a July 1, 2026 alert warning of an unusually early West Nile virus season with record case counts, urging Americans to use mosquito bite prevention through the July 4th Independence Day holiday weekend. ^[10]

NIPAH VIRUS — INDIA (KERALA)

• On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male developed neurological symptoms on May 30 and was hospitalized June 10.
• Earlier in 2026, India reported two NiV-infected healthcare workers in West Bengal in January, and Bangladesh confirmed one NiV case in Rajshahi Division in February.

HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

• The Andes hantavirus outbreak linked to the M/V Hondius cruise ship has now spanned four WHO Disease Outbreak News reports since first notification on May 2, 2026; over 120 passengers from 23 countries were safely disembarked in Tenerife.
• As of the May 13 DON update, two laboratory-confirmed cases and additional suspected cases were identified; CDC provided ongoing response updates through late June 2026.

YELLOW FEVER — GLOBAL

• From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas that surged in 2025 carried into 2026.

MEASLES — BANGLADESH AND GLOBAL

• Bangladesh reported 19,161 suspected measles cases spanning 58 of 64 districts across all eight national divisions as of early April 2026, a nationwide surge.
• Worldwide, measles infected 10.3 million people in 2023; a 2025 outbreak in Texas resulted in at least two deaths, underscoring persistent vaccination gaps.

MERS-COV — GLOBAL

• Since January 2025 through December 21, 2025, WHO recorded 19 MERS-CoV cases globally including four deaths; 17 were from Saudi Arabia and two from France.

MPOX — RECOMBINANT STRAIN

• In February 2026, WHO reported two cases of a recombinant monkeypox virus strain combining genomic elements of both clade Ib and clade IIb MPXV — recombination occurring via dual infection of the same individual.

DRUG-RESISTANT BACTERIA

• A September 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in the United States, amplifying concern about the antimicrobial resistance threat in healthcare settings.

🧬 LONGEVITY & AGING

INFECTION-TO-DEMENTIA PATHWAY

• Two linked commentaries in Lancet Healthy Longevity (Sipilä/Kivimäki, and Penfold/Jiwaji/MacLullich) propose delirium — acute brain confusion during severe infection — as a missing mechanistic link connecting serious infections to later-life dementia development.
• The hypothesis suggests that infection-triggered neuroinflammation, experienced as delirium, may accelerate or initiate neurodegenerative processes — with implications for post-sepsis and post-Ebola survivor follow-up.

MUSCLE AGING AND THE CELL NUCLEUS

• A study in Nucleus (Esen, Battey, Stroud, Kirby) identifies the cell nucleus as a mechanobiological hub in skeletal muscle aging, with nuclear mechanical properties deteriorating in aged muscle and potentially driving age-related loss of muscle function.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

• A Finnish study in Scandinavian Journal of Primary Health Care (Rotonen et al.) found an association between insulin resistance and mild cognitive impairment during aging, with reduced health-related quality of life amplifying the relationship.

CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AND GUT

• A Gut Microbes paper (Xu, Snelson, Marques) examines cardiovascular-kidney-metabolic (CKM) syndrome through the lens of gut-derived uremic toxins, arguing microbiome-produced compounds accelerate simultaneous heart, kidney, and metabolic decline — a key cluster in aging populations.

AURICULAR CHONDROCYTE SENESCENCE STUDY

• Researchers (Alemujiang et al., Regenerative Therapy) identified a conserved nine-gene module in long-term expandable auricular chondrocytes that drives dedifferentiation independently of classical cellular senescence — a finding relevant to tissue engineering and age-related cartilage repair.

CHRONIC KIDNEY DISEASE AND MULTIMORBIDITY

• The UK NURTuRE-CKD multicentre cohort study (Boateng et al., Annals of Medicine) found that multiple long-term conditions compound mortality risk, kidney failure progression, and quality-of-life deterioration in CKD patients — a common aging comorbidity cluster.

CARDIORENAL BIOMARKERS VIA PROTEOMICS

• A Mendelian randomization plus machine-learning study in Renal Failure (Huang et al.) identified causal plasma protein biomarkers linking cardiovascular and kidney disease comorbidity, potentially enabling earlier detection of cardiorenal aging trajectories.

💊 NEW CURES & APPROVALS

SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE

• AbbVie received two supplemental approvals (BLA761105 and BLA761262) for Skyrizi (risankizumab-rzaa), an IL-23 inhibitor used across immune-mediated inflammatory indications including Crohn's disease, ulcerative colitis, and plaque psoriasis.

ROMVIMZA (VIMSELTINIB) — DECIPHERA PHARMACEUTICALS

• Deciphera Pharmaceuticals received a supplemental approval for Romvimza (vimseltinib), a CSF1R kinase inhibitor indicated for tenosynovial giant cell tumor, a rare debilitating joint disease.

SARCLISA (ISATUXIMAB-IRFC) — SANOFI AVENTIS US

• Sanofi received a supplemental approval for Sarclisa (isatuximab-irfc), a CD38-targeting monoclonal antibody for multiple myeloma, a blood cancer affecting primarily older adults.

BESREMI (ROPEGINTERFERON ALFA-2B-NJFT) — PHARMAESSENTIA

• PharmaEssentia received a supplemental approval for Besremi (ropeginterferon alfa-2b-njft), a long-acting interferon for polycythemia vera, a myeloproliferative blood disorder.

RINVOQ LQ (UPADACITINIB) — ABBVIE

• AbbVie received a supplemental approval for Rinvoq LQ (upadacitinib liquid formulation), a JAK1 inhibitor used in rheumatoid arthritis, atopic dermatitis, and other inflammatory conditions.

ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — ISTX

• ISTX received a supplemental approval for Zevtera (ceftobiprole medocaril sodium), a broad-spectrum anti-MRSA cephalosporin antibiotic for serious bacterial infections.

OSELTAMIVIR PHOSPHATE — ALEMBIC PHARMACEUTICALS

• Alembic received an original (new) ANDA approval for generic oseltamivir phosphate (the active ingredient in Tamiflu), expanding generic influenza antiviral supply — notably relevant amid ongoing H5N1 and seasonal flu concerns.

🧪 CLINICAL TRIALS

CONNECTING TODAY — DEMENTIA AND SOCIAL ISOLATION (NCT07182019)

• A newly registered trial (July 1, 2026) will recruit 80 care home residents with moderate-to-severe dementia to evaluate a remote video-call program — Connecting Today — designed to reduce social isolation, a recognized accelerant of cognitive decline.

DIGITAL HEALTH FOR PSP AND LEWY BODY DEMENTIA (NCT07240805)

• BioSensics, Johns Hopkins, and Massachusetts General Hospital are running a trial of wearable digital health technologies to track motor progression in progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and dementia with Lewy bodies (DLB).

H01 FOR INTERSTITIAL LUNG DISEASE — THE SOLIS STUDY (NCT06325696)

• An NIH-supported trial is testing investigational compound H01 in adults with interstitial lung disease, which causes progressive pulmonary fibrosis; most patients with this condition die within years of diagnosis.

KNEE OSTEOARTHRITIS — DAILY KNEE SLEEVE USE (NCT07674901)

• A new superiority RCT (registered July 1, 2026) will enroll 235 adults aged 50 to 64 with chronic knee pain to assess whether daily knee sleeve use slows 5-year radiographic osteoarthritis progression — targeting a condition that is a leading driver of disability in aging populations.

INTRA-ARTICULAR OZONE FOR KNEE OSTEOARTHRITIS (NCT07678996)

• A July 2026 trial will evaluate dose-response effects of intra-articular ozone injections combined with exercise in patients aged 40 to 75 with Grade 2 to 3 knee osteoarthritis, testing doses of 10, 20, and other concentrations.

INSULIN RESISTANCE AND COGNITION CONTEXT

• The association study (Rotonen et al.) linking insulin resistance to mild cognitive impairment in aging populations reinforces the scientific rationale for ongoing metabolic intervention trials targeting brain health in older adults.

📢 PUBLIC HEALTH

WEST NILE VIRUS HOLIDAY ALERT

• CDC is urging Americans to apply EPA-registered repellents, wear long sleeves, and eliminate standing water over the July 4th weekend as West Nile virus cases are running at record early-season pace across the US. ^[10]

LISTERIA — REQUESÓN AND SOFT RICOTTA CHEESE

• CDC warned on June 5, 2026 of a Listeria monocytogenes outbreak linked to requesón and soft ricotta cheese; consumers are advised to avoid these products until further notice.

SALMONELLA — BACKYARD POULTRY, 13 STATES

• As of April 23, 2026, 34 people across 13 states have been sickened with the same Salmonella strain linked to backyard poultry; children under 5 account for over one quarter of cases.

TICK BITE ER VISITS ABOVE SEASONAL NORM

• CDC data as of April 23, 2026 show weekly emergency room visits for tick bites are running higher than usual for this point in the season, prompting public health guidance on tick checks and repellent use.

INFANT BOTULISM — NARA ORGANICS FORMULA

• CDC issued a June 13, 2026 outbreak update urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to confirmed infant botulism cases.

WORLD SCREWWORM — CDC EMERGENCY OPERATIONS

• CDC activated its Emergency Operations Center on June 12, 2026 in response to a New World screwworm (Cochliomyia hominivorax) threat; this parasitic fly can infest living tissue in humans and animals.

IMMUNIZATION SCHEDULE UPDATES

• CDC's June 25 to 26, 2025 ACIP meeting concluded with a joint statement; separately, the 2025 to 2026 schedule shifted to individual-based decision-making for COVID-19 vaccination and adopted standalone chickenpox vaccination for toddlers.
• ACIP voted in December 2025 to recommend individual-based decision-making (rather than universal recommendation) for hepatitis B vaccine in infants born to hepatitis B-negative mothers; CDC formally adopted the change December 16, 2025.

PNEUMOCOCCAL VACCINE AGE LOWERED

• CDC Director Mandy Cohen in October 2024 endorsed ACIP's recommendation to lower the recommended age for pneumococcal vaccination from 65 to 50 years old, expanding protection against pneumococcal disease into midlife.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
5. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
6. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
7. CDC Mobilizes International Response Following Ebola Disease Outbreak in DRC and Uganda — CDC Newsroom
8. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
10. CDC Encourages Americans to Stay Mosquito Bite-Free during America's 250th Independence Day holiday weekend — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260702-02-v17 · 2026-07-02 02:02 UTC